Hepatobiliary Oncology
Clinical research activity is centred on intermediate stage hepatocellular carcinoma, with attention to treatment strategies for liver cancer managed in a specialist oncology setting.
- Hepatocellular carcinoma
- Intermediate-stage liver cancer
- Oncology
The focus reflects interest in disease management for patients whose cancer remains confined to the liver and requires coordinated oncological care.
Locoregional Liver Cancer Treatment
Research activity includes transarterial chemoembolisation and transarterial embolisation, supporting investigation of liver-directed treatment options for tumour control.
- TACE
- TAE
- Liver-directed therapy
These areas are relevant to patients receiving interventional treatment for unresectable intermediate-stage disease.
Immuno-Oncology
The sponsor is involved in studies combining nivolumab with liver-directed treatment, reflecting interest in immune checkpoint inhibition for solid tumours in the liver.
- Nivolumab
- Immune checkpoint therapy
- Combination cancer treatment
This area links systemic immunotherapy with locoregional approaches in the management of hepatobiliary malignancy.
Survival and Treatment Outcomes
Clinical interest extends to survival outcomes and comparative effectiveness in patients with intermediate-stage liver cancer, with emphasis on treatment benefit in routine specialist care.
- Overall survival
- Comparative treatment outcomes
- Randomised cancer research
Work in this area supports evaluation of how different therapeutic approaches perform for patients with locally advanced liver disease.
